Inhaled formoterol impairs aerobic exercise capacity in endurance-trained individuals: a randomised controlled trial.

ABSTRACT:

Background

The 2022 Global Initiative for Asthma guidelines emphasise the inhaled long-acting β₂-agonist formoterol as part of the first treatment step, and therefore formoterol use among athletes will probably increase. However, prolonged supratherapeutic use of inhaled β₂-agonists impairs training outcomes in moderately trained men. We investigated whether inhaled formoterol, at therapeutic doses, imposes detrimental effects in endurance-trained individuals of both sexes.

Methods

51 endurance-trained participants (31 male, 20 female; mean±sd maximal oxygen consumption (V̇ _{O2 max}) 62±6 mL·min^-1·kg bw^-1 and 52±5 mL·min^-1·kg bw^-1, respectively) inhaled formoterol (24 µg;

SUBMITTER: Jessen S 

PROVIDER: S-EPMC10123513 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature